Sales & Earnings

New product launches come with great expectations, which are sometimes unrealistic. This can lead to disappointment. Lately, market access restrictions are exacerbating sales challenges.

Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.

The biotechnology and pharmaceutical sectors outsource much of their drug discovery and clinical development efforts to contract organizations. Investors’ reduced appetite for biotech is now impacting those contractors.

The Duchenne drug Agamree has started so well in Germany and Austria that the Swiss company is expanding its self-marketing strategy in the top five European markets to include the Nordics, Portugal and Ireland.

As it navigates product transition in ophthalmology against biosimilar and branded rivals, Regeneron seems to have a simpler challenge in another major therapeutic area.

The company laid out a growth strategy to investors centered on three business units, $4bn in revenue by 2027 and $500m in cost savings. 

Pointing to capacity constraints and an ever-increasing global demand, Aspen has trumpeted its prospects in GLP-1s after striking a deal that could have a significant impact for the firm, both commercially and from a manufacturing standpoint.

Henlius’ results for the first half of 2024 have shown a continued trend in growing sales of its core biological products on the backdrop of the company’s ongoing privatization by parent company Fosun Pharmaceutical.